Cardiff Current Deferred Revenue from 2010 to 2024
| CRDF Stock | USD 3.21 0.09 2.88% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 5.2 M | Current Value 5.5 M | Quarterly Volatility 3 M |
Check Cardiff Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cardiff Oncology's main balance sheet or income statement drivers, such as Selling General Administrative of 7.5 M, Other Operating Expenses of 48.2 M or Research Development of 34.5 M, as well as many indicators such as Price To Sales Ratio of 201, Dividend Yield of 0.0074 or PTB Ratio of 0.9. Cardiff financial statements analysis is a perfect complement when working with Cardiff Oncology Valuation or Volatility modules.
Cardiff | Current Deferred Revenue |
Latest Cardiff Oncology's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Cardiff Oncology over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Cardiff Oncology's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cardiff Oncology's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Cardiff Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 1,471,308 | |
| Coefficient Of Variation | 204.66 | |
| Mean Deviation | 2,797,272 | |
| Median | 589.00 | |
| Standard Deviation | 3,011,248 | |
| Sample Variance | 9.1T | |
| Range | 7.3M | |
| R-Value | 0.95 | |
| Mean Square Error | 924B | |
| R-Squared | 0.91 | |
| Slope | 640,689 | |
| Total Sum of Squares | 126.9T |
Cardiff Current Deferred Revenue History
About Cardiff Oncology Financial Statements
Cardiff Oncology stakeholders use historical fundamental indicators, such as Cardiff Oncology's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Cardiff Oncology investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cardiff Oncology's assets and liabilities are reflected in the revenues and expenses on Cardiff Oncology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cardiff Oncology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 5.2 M | 5.5 M |
Currently Active Assets on Macroaxis
When determining whether Cardiff Oncology is a strong investment it is important to analyze Cardiff Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiff Oncology's future performance. For an informed investment choice regarding Cardiff Stock, refer to the following important reports:Check out the analysis of Cardiff Oncology Correlation against competitors. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.92) | Revenue Per Share 0.015 | Quarterly Revenue Growth 0.509 | Return On Assets (0.34) | Return On Equity (0.59) |
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.